Oncology Corporate Profile
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six targeted therapeutic oncology therapeutics in clinical development.
|Onivyde__¢||irinotecan liposome injection||ONIVYDE is a topoisomerase inhibitor indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. |
|Brand / Product||Class||Area of Study||Phase||Partnership|
|MM-398||nanotherapeutic||2nd line metastatic Pancreatic cancer||III|
|MM-111 (+ aclitaxel and trastuzumab)||bi-specific antibody (anti-ErbB3 & anti-ErbB2)||2nd line metastatic Gastric cancer||II|
|MM-121 (+ paclitaxel)||anti-erbb3 monoclonal antibody||Breast cancer||II|
|MM-121 (+ exemestane)||anti-erbb3 monoclonal antibody||Breast cancer||II|
|MM-302||nanotherapeutic||Breast cancer (HER2+)||II|
|MM-121 (+ erlotinib)||anti-erbb3 monoclonal antibody||Non Small Cell Lung Cancer (NSCLC)||II|
|MM-121||anti-erbb3 monoclonal antibody||Non Small Cell Lung Cancer (NSCLC)||II|
|MM-121 (+ paclitaxel)||anti-erbb3 monoclonal antibody||Ovarian cancer||II|
|MM-141||bi-specific tetravalent antibody (ErbB3 & IGF-1R)||Various cancer types||I|
|MM-141 (+ everolimus and docetaxel)||bi-specific tetravalent antibody (ErbB3 & IGF-1R)||Various cancer types||I|
|MM-310||antibody-directed nanotherapeutic (ADN)||Various cancer types||I|
|MM-151||anti-egfr oligoclonal antibody||Various cancer types||I|
|MM-131||multispecific antibody||Various cancer types||Preclinical|
View additional information on product candidates here »
3/27/2017 11:00 am
[PR Newswire] - CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data from its oncology pipeline at the 2017 ...
3/24/2017 06:04 pm
3/23/2017 05:02 pm
3/23/2017 11:00 am
[PR Newswire] - CAMBRIDGE, Mass., March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. "The initiation of this study is an important step in evaluating MM-310's safety and preliminary activity in patients diagnosed with solid tumors," said Vasileios Askoxylakis, MD, PhD, Medical Director and MM-310 Project Leader at Merrimack.
3/15/2017 01:03 pm
3/14/2017 07:00 pm
3/8/2017 02:03 pm
[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 8, 2017 / Biotech and Pharmaceutical companies were under attack Tuesday after President Trump tweeted, "I am working on a new system where there will be competition ...
3/7/2017 06:00 pm
3/2/2017 10:00 pm
3/2/2017 06:02 pm
3/1/2017 04:05 pm
3/1/2017 02:05 pm
3/1/2017 01:05 pm
3/1/2017 12:02 pm
3/1/2017 12:02 pm
3/1/2017 12:01 pm
3/1/2017 12:00 pm
[PR Newswire] - CAMBRIDGE, Mass., March 1, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its fourth quarter and full year 2016 financial results for the period ended December 31, ...
2/22/2017 09:00 pm
[PR Newswire] - The call will cover an update on Merrimack's recent progress as well as a summary of fourth quarter and full year 2016 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts.
2/17/2017 08:00 pm
2/12/2017 01:04 pm
2/11/2017 07:00 pm
2/7/2017 11:02 pm